scholarly journals Diagnosis of Peripheral Facial Palsy Associated with Parvovirus B19 Infection by Polymerase Chain Reaction

2022 ◽  
Vol 2022 ◽  
pp. 1-3
Author(s):  
Taro Fukuta ◽  
Yoshihiko Kawano ◽  
Maiko Ikeda ◽  
Jun-ichi Kawada ◽  
Yoshinori Ito ◽  
...  

Human parvovirus B19 (PVB19) infection causes neurological manifestations, including encephalitis, meningitis, and neuropathy, but facial nerve palsy is rare. Moreover, no case of facial nerve palsy related to PVB19 infection that was diagnosed by PCR and serology has been reported. A 19-month-old boy without the medical history developed facial nerve palsy and was treated with prednisolone and valacyclovir. On the 19th day, erythema appeared on his body, and the PVB19-specific IgM and PVB19 DNA were detected in the serum, leading to the diagnosis of infectious erythema associated with PVB19 infection. This case indicates that PVB19 may be one of the causative agents of facial nerve palsy.

1992 ◽  
Vol 24 (6) ◽  
pp. 691-696 ◽  
Author(s):  
Tino F. Schwarz ◽  
Gundula Jäger ◽  
Wolfgang Holzgreve ◽  
Michael Roggendorf

1994 ◽  
Vol 108 (8) ◽  
pp. 676-678 ◽  
Author(s):  
Yoshiharu Watanabe ◽  
Minoru Ikeda ◽  
Nobuo Kukimoto ◽  
Mutsumi Kuga ◽  
Hiroshi Tomita

AbstractWe examined a very unusual patient who developed peripheral facial palsy with chickenpox. A survey of the English literature revealed that eight such patients had been reported, but the period between the appearance of the vesicles of varicella and the facial nerve palsy ranged from five days before to 16 days after the eruption development. We presume that the route of infection was neurogenous in patients who had palsy after the appearance of the eruptions, but haematogenous in patients who had palsy before the appearance of vesicles. The two patients whose infection route was presumed to be haematogenous, had a poor prognosis.


1993 ◽  
Vol 44 (2-3) ◽  
pp. 155-165 ◽  
Author(s):  
Edison L. Durigon ◽  
Dean D. Erdman ◽  
G.William Gary ◽  
Mark A. Pallansch ◽  
Thomas J. Torok ◽  
...  

1994 ◽  
Vol 72 (04) ◽  
pp. 503-507 ◽  
Author(s):  
A Große-Bley ◽  
A M Eis-Hübinger ◽  
R Kaiser ◽  
J Oldenburg ◽  
H H Brackmann ◽  
...  

SummaryIt is known that parvovirus B19 (B19) is transmitted to hemophiliacs by clotting factors prepared from human plasma. However, it is not clear whether B19 is also transmitted by the more recently used inactivated clotting factor preparations. Therefore, we investigated 69 hemophiliacs, mostly children, receiving only virus-inactivated clotting factors. 49 of them (71%) were B19 IgG-positive and 18 of the IgG-positive hemophiliacs (37%) were also B19 IgM-positive. In contrast, out of 73 age-matched controls only 10 (14%) were IgG-positive, two of them being also IgM-positive. In hemophiliacs treated before 1984 with noninactivated clotting factors, seroprevalence was very similar: 94/136 (69%) presented B19 IgG antibodies as compared to their age-matched controls with 16/50 (32%). Out of the 94 IgG-positive patients 24 (26%) were IgM-positive, whereas IgM antibodies were never found in 16 sera of 16 IgG-positive controls. In 4 out of 24 IgM positive hemophiliacs, B19 DNA was detected in the sera by using the polymerase chain reaction. However, B19 DNA was also found in 3/69 anti-B19 IgM-negative, HIV-infected hemophiliacs (all three patients in CDC stage IV). Since it seems unlikely that the results only represent passive acquisition of B19 DNA from blood products and induction of antibodies by immunization with inactivated antigen, the observations rather suggest that infection with B19 is transmitted by clotting factors, including those treated for virus inactivation.


Sign in / Sign up

Export Citation Format

Share Document